Background: Gastric cancer is among the most lethal human malignancies. Previous studies have identified molecular aberrations that constitute dynamic biological networks and genomic complexities of gastric tumors. However, the clinical translation of molecular-guided targeted therapy is hampered by challenges. Notably, solid tumors often harbor multiple genetic alterations, complicating the development of effective treatments.
Methods: To address such challenges, we established a comprehensive dataset of molecularly annotated patient derivatives coupled with pharmacological profiles for 60 targeted agents to explore dynamic pharmacogenomic interactions in gastric cancers.
Results: We identified lineage-specific drug sensitivities based on histopathological and molecular subclassification, including substantial sensitivities toward VEGFR and EGFR inhibition therapies in diffuse- and signet ring-type gastric tumors, respectively. We identified potential therapeutic opportunities for WNT pathway inhibitors in ALK-mutant tumors, a significant association between PIK3CA-E542K mutation and AZD5363 response, and transcriptome expression of RNF11 as a potential predictor of response to gefitinib.
Conclusions: Collectively, our results demonstrate the feasibility of drug screening combined with tumor molecular characterization to facilitate personalized therapeutic regimens for gastric tumors.
Keywords: Gastric cancer; Gefitinib; PIK3CA-E542K; Pharmacogenomics; RNF11.
Conflict of interest statement
Do-Hyun Nam is the CEO of AimedBio Inc. and owns shares of AimedBio Inc. which owns IPs for Avatascan. The remaining authors declare that they have no competing interests.
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3. Genome Biol. 2019. PMID: 31771620 Free PMC article.
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30. Ther Adv Respir Dis. 2016. PMID: 26620497 Free PMC article. Review.
Molecular profiling of small cell lung cancer in a Japanese cohort.Lung Cancer. 2014 May;84(2):139-44. doi: 10.1016/j.lungcan.2014.02.013. Epub 2014 Mar 3. Lung Cancer. 2014. PMID: 24657128
Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Discov Med. 2013 Aug;16(86):7-14. Discov Med. 2013. PMID: 23911227 Review.
Classifying cancer genome aberrations by their mutually exclusive effects on transcription.BMC Med Genomics. 2017 Dec 21;10(Suppl 4):66. doi: 10.1186/s12920-017-0303-0. BMC Med Genomics. 2017. PMID: 29322935 Free PMC article.